Title: LegoChem Bio, Original technology to lead to additional licensing out agreements in 2014
Author: Woori Investment & Securities / Brian Lee
Date: 2013-11-18
Pages: 6
Download the attachment at the bottom of the page.

URL to the source

 
* We are not responsible for this content nor do we necessarily endorse any opinion contained in this material. We make no warranties or representations, express or implied, about the content, including as to its legality or accuracy.

Summary of Contents

o  LegoChem's proprietary scaffolds can swiftly uncover new drug candidates.
o  Seven licensing-out deals were made, including two overseas contracts.
o  Retains ability to generate new drug candidates, proprietary ADC technology, and licensing experiences with Big Pharmas.
o  Company's financial performance is expected to turn around in 2014 with additional licensing-out deals and incoming milestones. 
 

Table of Contents

1. Summary

 
2. Domestic / overseas licensing-out agreements

3. R&D outcomes

4. Licensing-out deals

5. Major R&D pipelines

6. Earnings forecasts

7. Peer valuations

8. Share price performance

9. Major shareholders